ArticleAnnals of surgical oncology2019
DCIS with Microinvasion: Is It In Situ or Invasive Disease?
Article in Annals of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis.Breast cancer research and treatment · 2023Pooled it
- Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis.Cancer medicine · 2022Trial
- Case Report: Liver Metastasis from Ductal Carcinoma In Situ of the Breast.International medical case reports journal · 2026Article
- Refining Sentinel Lymph Node Biopsy Decisions for Clinically Node-Negative Microinvasive DCIS.The breast journal · 2026Article
- Predictors and nomogram for upstaging to invasive breast carcinoma in ductal carcinomaGland surgery · 2025Article
- Invasion prediction with artificial intelligence in ductal carcinoma in situ (DCIS) patients: a proof-of-concept study.BMC surgery · 2025Article
- Article
- Ultrasonography in granulomatous mastitis: diagnostic differentiation, treatment response, and prognostic value.American journal of translational research · 2025Article
- Case Report: Breast ductal carcinomaFrontiers in oncology · 2025Article
- The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study.Therapeutic advances in medical oncology · 2025Article
- Ductal Carcinoma In Situ of the Breast in Sclerosing Adenosis Mimicking Microinvasive Ductal Carcinoma: A Rare Case Report.Clinical case reports · 2024Article
- The diagnostic value of contrast-enhanced ultrasound combined with clinicopathological features in microinvasive ductal carcinomaGland surgery · 2024Article
- Unveiling the Clinical Path of Microinvasive Breast Cancer: A Comparative Study With Tis-T1 Breast Cancer.Cancer medicine · 2024Article
- Feasibility analysis of magnetic resonance imaging-based radiomics features for preoperative prediction of nuclear grading of ductal carcinoma in situ.Gland surgery · 2023Article
- A clinical radiomics nomogram preoperatively to predict ductal carcinoma in situ with microinvasion in women with biopsy-confirmed ductal carcinoma in situ: a preliminary study.BMC medical imaging · 2023Article
- Article
- Delayed Sentinel Lymph Node Dissection in Patients with a Preoperative Diagnosis of Ductal Cancer In Situ by Preoperative Injection with Superparamagnetic Iron Oxide (SPIO) Nanoparticles: The SentiNot Study.Annals of surgical oncology · 2023Article
- Prognostic Markers of Microinvasive Breast Carcinoma: A Systematic Review and Meta-Analysis.Cancers · 2023Review
- Ductal Carcinoma In Situ (DCIS) and Microinvasive DCIS: Role of Surgery in Early Diagnosis of Breast Cancer.Healthcare (Basel, Switzerland) · 2023Review
- Clinicopathological characteristics, treatments, and prognosis of breast ductal carcinoma in situ with microinvasion: A narrative review.Chronic diseases and translational medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundDuctal carcinoma in situ (DCIS) with microinvasion (DCISM) can be challenging in balancing the risks of overtreatment versus undertreatment. We compared DCISM, pure DCIS, and small volume (T1a) invasive ductal carcinoma (IDC) as related to histopathology, treatment patterns, and survival outcomes.
methodsWomen ages 18-90 years who underwent breast surgery for DCIS, DCISM, or T1a IDC were selected from the SEER Database (2004-2015). Multivariate logistic regression and Cox proportional hazards models were used to estimate the association of diagnosis with treatment and survival, respectively.
resultsA total of 134,569 women were identified: 3.2% DCISM, 70.9% DCIS, and 25.9% with T1a IDC. Compared with invasive disease, DCISM was less likely to be ER+ or PR+ and more likely to be HER2+. After adjustment, DCIS and invasive patients were less likely to undergo mastectomy than DCISM patients (DCIS: OR 0.53, 95% CI 0.49-0.56; invasive: OR 0.86, CI 0.81-0.92). For those undergoing lumpectomy, the likelihood of receiving radiation was similar for DCISM and invasive patients but lower for DCIS patients (OR 0.57, CI 0.52-0.63). After adjustment, breast-cancer-specific survival was significantly different between DCISM and the other two groups (DCIS: HR 0.59, CI 0.43-0.8; invasive: HR 1.43, CI 1.04-1.96). However, overall survival was not significantly different between DCISM and invasive disease, whereas patients with DCIS had improved OS (HR 0.83, CI 0.75-0.93).
conclusionsAlthough DCISM is a distinct entity, current treatment patterns and prognosis are comparable to those with small volume IDC. These findings may help providers counsel patients and determine appropriate treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.